Trending NewsTrending NewsNYSE:TEVA Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis $43.52 +0.29 (+0.66%) Closing price 11/12/2026 03:59 PM EasternExtended Trading$43.85 +0.33 (+0.75%) As of 11/12/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Teva Pharmaceutical Industries Stock (NYSE:TEVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TEVA alerts:Sign Up Key Stats Today's Range$43.19▼$44.3150-Day Range$36.34▼$43.5352-Week Range$24.01▼$44.31Volume9.25 million shsAverage Volume6.98 million shsMarket Capitalization$50.72 billionP/E Ratio19.13Dividend YieldN/APrice Target$48.15Consensus RatingModerate Buy Company Overview Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions. Teva is headquartered in Tel Aviv, Israel. Richard Francis has served as the company’s president and chief executive officer since 2023.AI Generated. May Contain Errors. Read More Teva Pharmaceutical Industries Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreTEVA MarketRank™: 4.35783416165 of 5 starsTeva Pharmaceutical Industries scored higher than 87% of companies evaluated by MarketBeat, and ranked 40th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTeva Pharmaceutical Industries has a consensus price target of $48.15, representing about 10.6% upside from its current price of $43.53.Amount of Analyst CoverageTeva Pharmaceutical Industries has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Teva Pharmaceutical Industries' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth55.56% Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 55.56% in the coming year, from $1.98 to $3.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is 19.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.14.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is 19.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.50.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 4.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 6.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Teva Pharmaceutical Industries' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.39% of the float of Teva Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently decreased by 1.18%, indicating that investor sentiment is improving. Dividend0.8 / 5Dividend StrengthN/A Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 32.82% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend. News and Social Media3.6 / 5News Sentiment0.74 News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Teva Pharmaceutical Industries this week, compared to 10 articles on an average week.Search Interest14 people have searched for TEVA on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,061,351.00 in company stock.Percentage Held by Insiders0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Teva Pharmaceutical Industries' insider trading history. Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEVA Stock News HeadlinesHC Wainwright Has Positive Forecast for TEVA FY2026 Earnings55 minutes ago | americanbankingnews.comTeva Pharmaceutical R&D Day 2026: First-in-class drugs for Tourette syndrome, celiac disease, and IBD scarringNovember 11 at 11:49 PM | msn.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th. | Behind the Markets (Ad)Teva Pharmaceutical Industries Ltd: Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6-7 Billion in Innovative Medicines Revenue ...November 11 at 1:48 PM | finanznachrichten.deSector Update: Healthcare Stocks Softer in Afternoon TradingNovember 11 at 1:48 PM | finance.yahoo.comTeva outlines 2030 targets ahead of R&D Day eventNovember 11 at 8:48 AM | msn.comTeva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030November 11 at 8:48 AM | finance.yahoo.comTeva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030November 11 at 7:30 AM | globenewswire.comSee More Headlines TEVA Stock Analysis - Frequently Asked Questions How have TEVA shares performed this year? Teva Pharmaceutical Industries' stock was trading at $31.21 at the start of the year. Since then, TEVA stock has increased by 39.5% and is now trading at $43.5250. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced its quarterly earnings data on Tuesday, November, 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.14. The business's quarterly revenue was down 1.9% compared to the same quarter last year. Read the conference call transcript. Who are Teva Pharmaceutical Industries' major shareholders? Top institutional investors of Teva Pharmaceutical Industries include Phoenix Financial Ltd. (3.66%), Migdal Insurance & Financial Holdings Ltd. (3.38%), State Street Corp (1.66%) and William Blair Investment Management LLC (0.53%). Insiders that own company stock include Richard D Francis, Eric A Hughes, Mark Sabag, Tal Zvi Zaks, Eliyahu Sharon Kalif, Christine Fox, Richard Daniell, Amir Weiss, Matthew Shields, Eric Drape, Brian Savage, Placid Jover, Vikki L Conway and Roberto Mignone. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), GE Aerospace (GE), Intel (INTC), Tesla (TSLA), AT&T (T), Bank of America (BAC) and Micron Technology (MU). Company Calendar Last Earnings11/03/2026Today11/12/2026Fiscal Year End12/31/2026Next Earnings (Estimated)1/27/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TEVA's financial health is in the Green zone, according to TradeSmith. TEVA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TEVA CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees33,950Year Founded1901Price Target and Rating Average Price Target for Teva Pharmaceutical Industries$48.15 High Price Target$57.00 Low Price Target$40.00 Potential Upside/Downside+10.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$0.43 Trailing P/E Ratio19.13 Forward P/E Ratio14.13 P/E Growth4.05Net Income$1.41 billion Net Margins2.94% Pretax Margin2.10% Return on Equity33.20% Return on Assets6.59% Debt Debt-to-Equity Ratio1.59 Current Ratio0.95 Quick Ratio0.74 Sales & Book Value Annual Sales$17.26 billion Price / Sales2.94 Cash Flow$3.76 per share Price / Cash Flow11.59 Book Value$6.85 per share Price / Book6.35Miscellaneous Outstanding Shares1,165,300,000Free Float1,159,003,000Market Cap$50.72 billion OptionableOptionable Beta0.97 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NYSE:TEVA) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
